Literature DB >> 27666784

When Should the Mitral Valve Be Repaired or Replaced in Patients With Ischemic Mitral Regurgitation?

Vincent Chan1, Olivier Levac-Martinho2, Benjamin Sohmer3, Elsayed Elmistekawy2, Marc Ruel4, Thierry G Mesana2.   

Abstract

BACKGROUND: Data comparing outcomes after repair versus replacement of chronic ischemic mitral regurgitation (MR) is evolving. Recent data suggest that repair is associated with recurrent MR, but not survival, when compared with replacement. However, it remains unclear when either surgical strategy should be applied based on preoperative mitral valve anatomy.
METHODS: Between 2001 and 2013, 161 patients underwent repair or replacement of chronic ischemic MR. The mean age of these patients was 68.2 ± 9.0 years, 44 (27%) were female, and concomitant coronary artery bypass grafting was performed in 126 (78%). The mean preoperative posterior leaflet angle was 27.7 ± 14.2 degrees, and the left ventricular ejection fraction was 41.2 ± 12.4%. Detailed preoperative assessments of mitral valve anatomy were determined by transesophageal echocardiography. Clinical and echocardiographic follow-up was for 4.6 ± 3.2 years and extended to 11.7 years.
RESULTS: Overall, perioperative death occurred in 6 (3.3%) patients; 2 patients died after valve repair and 4 after valve replacement. Five-year survival and freedom from recurrent MR (≥2+) rates were 74.0 ± 5.6% and 57.8 ± 8.0%, respectively, after valve repair and 69.4 ± 6.2% and 87.1 ± 7.0%, respectively, after valve replacement. Valve repair was associated with recurrent MR (≥2+) (hazard ratio [HR], 5.3 ± 3.3; p = 0.007), but not survival (HR, 0.9 ± 0.3; p = 0.8). Preoperative posterior leaflet tethering angle was associated with survival (HR, 1.09 ± 0.04; p = 0.005) and also recurrent MR (≥2+) (HR, 1.04 ± 0.02; p = 0.03) after valve repair. Based on a receiver operator curve describing the relationship between recurrent MR (≥2+) and posterior leaflet tethering angle, a threshold of 22 degrees was determined.
CONCLUSIONS: Surgical correction of chronic ischemic MR can be performed with favorable early and late results, although recurrent MR occurred more often after repair. Among patients who underwent repair of ischemic MR, a preoperative posterior leaflet tethering angle of 22 degrees or greater was associated with worse late outcomes.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27666784     DOI: 10.1016/j.athoracsur.2016.07.002

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Comparison of mitral competence after mitral repair with papillary muscle approximation versus papillary muscle relocation for functional mitral regurgitation.

Authors:  Koji Furukawa; Mitsuhiro Yano; Eisaku Nakamura; Masakazu Matsuyama; Masanori Nishimura; Katsuya Kawagoe; Kunihide Nakamura
Journal:  Heart Vessels       Date:  2017-08-12       Impact factor: 2.037

2.  Mid-term results of mitral valve repair for ischemic mitral regurgitation adjusted according to the degree of remodeling progression.

Authors:  Koji Furukawa; Mitsuhiro Yano; Eisaku Nakamura; Masanori Nishimura; Kunihide Nakamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-08-25

3.  Clinical Outcomes of a Customized Mitral Valve Plasty for Functional Mitral Regurgitation with a Low Ejection Fraction and Implications for Preoperative Right Ventricular Function.

Authors:  Koji Furukawa; Mitsuhiro Yano; Hirohito Ishii; Shuhei Sakaguchi; Kousuke Mori; Masanori Nishimura; Kunihide Nakamura
Journal:  Ann Thorac Cardiovasc Surg       Date:  2020-06-10       Impact factor: 1.520

4.  MitraClip Real-World Data: What Is Missing and Looking Into the Future.

Authors:  Thierry G Mesana
Journal:  Cardiovasc Revasc Med       Date:  2020-07-22

5.  Repair or replacement for severe ischemic mitral regurgitation: A meta-analysis.

Authors:  Xinxin Wang; Bo Zhang; Jian Zhang; Yongquan Ying; Chengchu Zhu; Baofu Chen
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.